Skip to main content

Table 1 Basic patient characteristics, SSA medication, dosing interval and interval between SSA administration and 68Ga-DOTATOC PET/CT examinations Pat: patient, M: male, F: female, w: weeks, d: days, mets: metastases

From: Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by 68Ga-DOTATOC PET/CT

Pat

Age

Sex

SSA medication

Time (d) between SSA and 68Ga-DOTATOC PET/CT Baseline

Time (d) between SSA and 68Ga-DOTATOC-PET/CT Study

Tumor burden*

1

74

M

Sandostatin LAR 30 mg/3 w

17

17

Liver mets 20–25%

2

73

F

Santostatin Autogel 120 mg /2 w

14

13

Liver mets < 5% lgll. mets, bone mets,

3

61

M

Santostatin Autogel /120 mg 2 w

7

6

Liver mets 20–25%

4

68

M

Santostatin Autogel 120 mg /4 w

27

25

Liver mets 20–25%

  1. *Tumor burden was estimated on the baseline 68Ga-DOTATOC-PET/CT